Business Wire

Qlik Introduces an Agentic Experience to Accelerate Data-to-Decision Journeys

14.5.2025 14:30:00 CEST | Business Wire | Press Release

Share

Qlik®, a global leader in data integration, data quality, analytics, and artificial intelligence, today introduced its new agentic experience at Qlik Connect® 2025. The agentic experience will provide a single, conversational interface allowing users across the enterprise to interact naturally with data, using specialized AI agents to quickly uncover insights, drive faster decisions, and boost productivity—bringing new simplicity to complex data-driven workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514617616/en/

Qlik has consistently pushed forward the possibilities of data exploration, visualization, and analytics. At the heart of this continuous innovation is the Qlik engine—a unique technology that indexes relationships across data, enabling the discovery of unexpected connections. The agentic experience builds directly on this engine, expanding the ability of both users and agents to intuitively access these relationships, surface insights, and take action across diverse data.

The agentic experience will enable users to access insights and take action simply by engaging in natural language dialogue. Operating seamlessly across Qlik Cloud—including data integration, data quality, and analytics solutions—the experience removes friction, providing fast, intuitive visibility for smarter decisions and higher productivity.

At Qlik Connect, the company demonstrated how specialized AI agents will support users within this new experience:

  • Introduced last year for unstructured data, Qlik Answers™ will bring together structured and unstructured data in a single natural language experience, delivering trusted answers and enabling automated actions.
  • Revealed for the first time at the event, a discovery agent will proactively identify critical risks and opportunities across applications and datasets, presenting insights and recommended actions through a personalized feed.
  • Demonstrated as a concept, a pipeline agent will allow users to describe desired business outcomes conversationally, prompting automated recommendations and design of necessary data pipelines.

As enterprises face unpredictable market conditions and increasing pressure to make critical decisions rapidly, investments in AI have grown. With its agentic experience, Qlik is focused on helping customers turn data into timely, high-quality decisions and results. Qlik’s agentic experience is specifically designed to empower teams to accelerate both decisions and productivity in rapidly changing environments.

“This new agentic experience is about removing the distance between data, decisions, and outcomes,” said Mike Capone, CEO of Qlik. “People want a seamless, conversational way to engage with their data—one that fits naturally into their work and delivers clear, trusted answers in context. We’ve built this experience to reflect how decisions actually get made in a business.”

“There’s a growing demand for AI that does more than generate responses—enterprises want systems that can reason across complex data, explain their outputs, and drive action,” said Megha Kumar, Research Vice President, Worldwide Analytics & AI, IDC. “Qlik Answers combines structured and unstructured data with automation in a governed, explainable framework. It’s a strong example of how agentic AI can support real enterprise decision-making.”

“We’re under constant pressure to make faster, better decisions with data that’s scattered across the business,” said Yuzuru Fukuda, Corporate Executive Officer - Senior EVP, Enterprise Division CEO, Fujitsu. “The ability to ask a question and get a trusted, contextual answer—across structured reports, unstructured content, and automated workflows—is exactly the kind of capability we’ve been waiting for. It has the potential to remove a lot of friction from how decisions actually get made.”

The Qlik agentic experience is scheduled to begin rolling out this summer, starting with private previews. Teams attending Qlik Connect can experience the agentic capabilities firsthand through live demos and executive briefings. To learn more about our new agentic AI experience, read our blog or reach out to your Qlik representative.

About Qlik

Qlik converts complex data landscapes into actionable insights, driving strategic business outcomes. Serving over 40,000 global customers, our portfolio provides advanced, enterprise-grade AI/ML, data integration, and analytics. Our AI/ML tools, both practical and scalable, lead to better decisions, faster. We excel in data integration and governance, offering comprehensive solutions that work with diverse data sources. Intuitive analytics from Qlik uncover hidden patterns, empowering teams to address complex challenges and seize new opportunities. As strategic partners, our platform-agnostic technology and expertise make our customers more competitive.

© 2025 QlikTech International AB. All rights reserved. All company and/or product names may be trade names, trademarks and/or registered trademarks of the respective owners with which they are associated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514617616/en/

Contacts

Media Contact
Keith Parker
keith.parker@qlik.com
512-367-2884

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye